JPWO2023026994A1 - - Google Patents
Info
- Publication number
- JPWO2023026994A1 JPWO2023026994A1 JP2023543884A JP2023543884A JPWO2023026994A1 JP WO2023026994 A1 JPWO2023026994 A1 JP WO2023026994A1 JP 2023543884 A JP2023543884 A JP 2023543884A JP 2023543884 A JP2023543884 A JP 2023543884A JP WO2023026994 A1 JPWO2023026994 A1 JP WO2023026994A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021135254 | 2021-08-21 | ||
PCT/JP2022/031434 WO2023026994A1 (ja) | 2021-08-21 | 2022-08-19 | ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2023026994A1 true JPWO2023026994A1 (ja) | 2023-03-02 |
Family
ID=85322137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023543884A Pending JPWO2023026994A1 (ja) | 2021-08-21 | 2022-08-19 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4389893A1 (ja) |
JP (1) | JPWO2023026994A1 (ja) |
WO (1) | WO2023026994A1 (ja) |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
ATE312834T1 (de) | 1989-12-20 | 2005-12-15 | Avi Biopharma Inc | Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
JP4148662B2 (ja) | 2000-08-10 | 2008-09-10 | 第一三共株式会社 | ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬 |
IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
ES2561851T3 (es) | 2002-11-25 | 2016-03-01 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
EP1964916B1 (en) | 2005-12-06 | 2012-08-01 | The University of Tokyo | Multi-purpose acylation catalayst and use thereof |
AU2007258117B2 (en) | 2006-05-05 | 2013-05-30 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
MX2009003729A (es) | 2006-10-09 | 2009-04-22 | Santaris Pharma As | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. |
ATE540118T1 (de) | 2006-10-18 | 2012-01-15 | Isis Pharmaceuticals Inc | Antisense-verbindungen |
KR101617472B1 (ko) | 2007-11-15 | 2016-05-02 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 모르폴리노 올리고머의 합성 방법 |
US8575305B2 (en) | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
US8541562B2 (en) | 2009-10-29 | 2013-09-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
EP2704749A1 (en) | 2011-05-05 | 2014-03-12 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
BR112014004902B1 (pt) | 2011-08-30 | 2022-02-08 | United Kingdom Research And Innovation | Peptídeo, composição farmacêutica ou medicamento compreendendo o dito peptídeo e uso do mesmo para tratar distrofia muscular de duchenne |
EP2791335B1 (en) | 2011-12-16 | 2018-11-14 | National University Corporation Tokyo Medical and Dental University | Chimeric double-stranded nucleic acid |
CN110055243B (zh) | 2011-12-28 | 2024-03-26 | 日本新药株式会社 | 反义核酸 |
ES2758451T3 (es) | 2012-09-19 | 2020-05-05 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
IN2015DN02238A (ja) | 2012-09-21 | 2015-08-21 | Univ Osaka | |
GB201314411D0 (en) | 2013-08-12 | 2013-09-25 | Medical Res Council | Peptide conjugates |
EP3109254B1 (en) | 2014-02-18 | 2018-04-11 | Osaka University | Crosslinked nucleoside and nucleotide |
US20150329609A1 (en) * | 2014-03-03 | 2015-11-19 | Sujata Acharjee | Chimeric dystrophin proteins to treat dystrophinopathies |
EP3647318B1 (en) | 2014-04-28 | 2021-06-30 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
PL3159409T3 (pl) | 2014-06-17 | 2020-05-18 | Nippon Shinyaku Co., Ltd. | Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a |
EP3221330A4 (en) | 2014-11-18 | 2018-08-29 | Zata Pharmaceuticals Inc. | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds |
MY187033A (en) * | 2015-06-24 | 2021-08-27 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
EP3473270B1 (en) | 2016-06-20 | 2022-11-30 | Genahead Bio, Inc. | Antibody-drug conjugate |
KR20200060443A (ko) * | 2017-09-22 | 2020-05-29 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
AU2019312692A1 (en) | 2018-08-02 | 2021-03-11 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US20220175817A1 (en) | 2019-04-08 | 2022-06-09 | National University Corporation Tokyo Medical And Dental University | Pharmaceutical Composition for Treating Muscle Disease |
US20220370491A1 (en) | 2019-09-18 | 2022-11-24 | National University Corporation Tokyo Medical And Dental University | Nucleic acid complex |
TW202140513A (zh) * | 2020-02-22 | 2021-11-01 | 日商Jcr製藥股份有限公司 | 人類運鐵蛋白受體結合肽 |
-
2022
- 2022-08-19 JP JP2023543884A patent/JPWO2023026994A1/ja active Pending
- 2022-08-19 EP EP22861282.6A patent/EP4389893A1/en active Pending
- 2022-08-19 WO PCT/JP2022/031434 patent/WO2023026994A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023026994A1 (ja) | 2023-03-02 |
EP4389893A1 (en) | 2024-06-26 |